Profound Medical Corp.
PRN.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.38M | 1.20M | 428.00K | 393.00K | 393.00K |
| Total Other Revenue | 7.60M | 6.68M | 6.82M | 6.81M | 6.05M |
| Total Revenue | 8.98M | 7.88M | 7.25M | 7.20M | 6.45M |
| Cost of Revenue | 3.41M | 3.05M | 2.81M | 2.82M | 2.57M |
| Gross Profit | 5.57M | 4.83M | 4.44M | 4.38M | 3.88M |
| SG&A Expenses | 22.41M | 19.98M | 19.23M | 18.62M | 16.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.07M | 38.54M | 36.51M | 35.82M | 32.58M |
| Operating Income | -33.09M | -30.66M | -29.26M | -28.62M | -26.13M |
| Income Before Tax | -31.38M | -27.74M | -28.16M | -28.70M | -28.88M |
| Income Tax Expenses | 7.00K | -152.00K | -137.00K | -128.00K | 307.00K |
| Earnings from Continuing Operations | -31.39 | -27.59 | -28.03 | -28.57 | -29.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.39M | -27.59M | -28.03M | -28.57M | -29.19M |
| EBIT | -33.09M | -30.66M | -29.26M | -28.62M | -26.13M |
| EBITDA | -32.32M | -29.83M | -28.40M | -27.73M | -25.29M |
| EPS Basic | -1.34 | -1.22 | -1.28 | -1.35 | -1.39 |
| Normalized Basic EPS | -0.84 | -0.77 | -0.80 | -0.85 | -0.78 |
| EPS Diluted | -1.34 | -1.22 | -1.28 | -1.35 | -1.39 |
| Normalized Diluted EPS | -0.84 | -0.77 | -0.80 | -0.85 | -0.78 |
| Average Basic Shares Outstanding | 94.64M | 91.38M | 88.10M | 84.73M | 84.24M |
| Average Diluted Shares Outstanding | 94.64M | 91.38M | 88.10M | 84.73M | 84.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
